Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPPGlobeNewsWire • 02/13/26
Wall Street Analysts Believe Disc Medicine, Inc. (IRON) Could Rally 48.62%: Here's is How to TradeZacks Investment Research • 01/28/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRONGlobeNewsWire • 01/27/26
Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources OfficerGlobeNewsWire • 01/12/26
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026GlobeNewsWire • 01/12/26
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock RunThe Motley Fool • 01/11/26
Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs TranscriptSeeking Alpha • 12/07/25
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/06/25
Disc Medicine, Inc. (IRON) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/19/25
Disc Medicine, Inc. (IRON) Presents at Stifel 2025 Healthcare Conference TranscriptSeeking Alpha • 11/18/25
What Makes Disc Medicine, Inc. (IRON) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 10/27/25
Does Disc Medicine, Inc. (IRON) Have the Potential to Rally 26.29% as Wall Street Analysts Expect?Zacks Investment Research • 10/22/25
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 10/21/25
Disc Medicine: NDA Submission And CNPV For Bitopertin Further Boost Shareholder ValueSeeking Alpha • 10/20/25
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 10/20/25
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated MilestonesGlobeNewsWire • 10/20/25
The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.Investors Business Daily • 10/17/25
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney WeekGlobeNewsWire • 10/17/25
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)GlobeNewsWire • 09/30/25
Disc Medicine, Inc. (IRON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/10/25